Complete Story
 

06/18/2013

REVLIMID (lenalidomide) is NOW INDICATED in relapsed or refractory mantle cell lymphoma (MCL)

REVLIMID (lenlidomide) is now indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.  READ MORE


< Back | Printer Friendly Page